Eupraxia Pharmaceuticals earnings were -$44.5M for the trailing 12 months ending Mar 31, 2026, with N/A growth year over year. The latest EPRX earnings report on Mar 31, 2026 announced Q1 2026 earnings of -$12.7M, down 24.3% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, EPRX reported annual earnings of -$38.6M, with 50% growth.
Eupraxia Pharmaceuticals Earnings Reports & History FAQ
What were Eupraxia Pharmaceuticals's earnings last quarter?
On EPRX's earnings call on Invalid Date, Eupraxia Pharmaceuticals (NASDAQ: EPRX) reported Q1 2026 earnings per share (EPS) of -$0.23, up 9.52% year over year. Total EPRX earnings for the quarter were -$12.65 million. In the same quarter last year, Eupraxia Pharmaceuticals's earnings per share (EPS) was -$0.21.
Is Eupraxia Pharmaceuticals profitable or losing money?
As of the last Eupraxia Pharmaceuticals earnings report, Eupraxia Pharmaceuticals is currently losing money. Eupraxia Pharmaceuticals's net profit (also called net income) for the twelve months ending Mar 31, 2026 was -$44.49 million, a 68.82% increase year over year.
What was EPRX's earnings growth in the past year?
As of Eupraxia Pharmaceuticals's earnings date in Invalid Date, Eupraxia Pharmaceuticals's earnings has grown year over year. EPRX earnings in the past year totalled -$44.49 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.